Last reviewed · How we verify
Fluticasone furoate/umeclidinium/vilanterol
Fluticasone furoate/umeclidinium/vilanterol is a Inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-2 agonist combination Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved for Chronic obstructive pulmonary disease (COPD) maintenance treatment, Asthma maintenance treatment (in some markets).
This triple-combination inhaler reduces airway inflammation and improves airflow by combining a corticosteroid, an anticholinergic, and a long-acting beta-2 agonist.
This triple-combination inhaler reduces airway inflammation and improves airflow by combining a corticosteroid, an anticholinergic, and a long-acting beta-2 agonist. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment, Asthma maintenance treatment (in some markets).
At a glance
| Generic name | Fluticasone furoate/umeclidinium/vilanterol |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-2 agonist combination |
| Target | Glucocorticoid receptor, M3 muscarinic receptor, beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Fluticasone furoate is an inhaled corticosteroid that suppresses airway inflammation. Umeclidinium is a long-acting muscarinic antagonist that relaxes airway smooth muscle by blocking acetylcholine receptors. Vilanterol is a long-acting beta-2 agonist that further relaxes bronchial smooth muscle. Together, these three agents provide anti-inflammatory and bronchodilatory effects for sustained airway opening.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Asthma maintenance treatment (in some markets)
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness
- Tachycardia
Key clinical trials
- Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma (PHASE4)
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study (PHASE4)
- Immuno-inflammatory Response of Erdosteine in COPD (NA)
- To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD (PHASE4)
- Outcomes of Once-Daily ICS/LABA/LAMA + PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations (PHASE4)
- A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma (PHASE3)
- 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone furoate/umeclidinium/vilanterol CI brief — competitive landscape report
- Fluticasone furoate/umeclidinium/vilanterol updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Fluticasone furoate/umeclidinium/vilanterol
What is Fluticasone furoate/umeclidinium/vilanterol?
How does Fluticasone furoate/umeclidinium/vilanterol work?
What is Fluticasone furoate/umeclidinium/vilanterol used for?
Who makes Fluticasone furoate/umeclidinium/vilanterol?
What drug class is Fluticasone furoate/umeclidinium/vilanterol in?
What development phase is Fluticasone furoate/umeclidinium/vilanterol in?
What are the side effects of Fluticasone furoate/umeclidinium/vilanterol?
What does Fluticasone furoate/umeclidinium/vilanterol target?
Related
- Drug class: All Inhaled corticosteroid/long-acting muscarinic antagonist/long-acting beta-2 agonist combination drugs
- Target: All drugs targeting Glucocorticoid receptor, M3 muscarinic receptor, beta-2 adrenergic receptor
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Respiratory/Pulmonology
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Indication: Drugs for Asthma maintenance treatment (in some markets)
- Compare: Fluticasone furoate/umeclidinium/vilanterol vs similar drugs
- Pricing: Fluticasone furoate/umeclidinium/vilanterol cost, discount & access